Article

Non-peptide AT2-receptor agonists.

Center for Cardiovascular Research, Charité-Universitätsmedizin Berlin, Hessische Str. 3-4, 10115 Berlin, Germany.
Current Opinion in Pharmacology (impact factor: 6.86). 12/2010; 11(2):187-92. DOI:10.1016/j.coph.2010.11.002
Source: PubMed

ABSTRACT The renin-angiotensin-system harbours two main receptor subtypes binding angiotensin II which are the AT1-receptor and the AT2-receptor. While the AT1-receptor has been a drug target in cardiovascular disease for many years, the AT2-receptor was only a subject of academic interest. This has changed with the design and synthesis of a first non-peptide, orally active AT2-receptor agonist, compound 21 (C21). First data using C21 revealed tissue protective effects and functional improvement after myocardial infarction and in hypertension-induced end organ damage, notably in a blood-pressure independent way. In all of these models, AT2-receptor mediated anti-inflammation seemed an important underlying mechanism. C21 is awaited to enter a phase I clinical study in 2011.

0 0
 · 
0 Bookmarks
 · 
55 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

academic interest
 
AT2-receptor
 
blood-pressure independent way
 
compound 21
 
First data
 
first non-peptide
 
hypertension-induced end organ damage
 
myocardial infarction
 
orally active AT2-receptor agonist
 
renin-angiotensin-system harbours
 
tissue protective effects